Drugs / CD19+CD20 dual CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07344818 | Jan 2026 → Mar 2027 expected | aggressive B-cell non-Hodgkin lymphoma | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19+CD20 dual CAR-T cells | “eligible patients will be treated with CD19+CD20 dual CAR-T cells” NCT07344818 ↗ |
| Modality | Cell therapy | “autologous CD19+CD20 dual CAR-T cells, single injection” NCT07344818 ↗ |